Document Type
Article
Publication Date
4-22-2022
Abstract
Advances in molecular biology and neuroscience have led to the discovery of calcitonin gene-related peptide (CGRP), a 37 amino-acid neuropeptide that plays a critical role in the pathogenesis of migraine. CGRP receptor antagonist, also known as gepant, is an oral medication that inhibits the CGRP-related nociceptive signaling pathway. To date, three gepants are approved by the FDA for migraine treatment. Atogepant is a 2nd-generation gepant that non-competitively antagonizes CGRP receptors inhibiting neurogenic inflammation and pain sensitization. With its long half-life and minimal cardiovascular or liver toxicity, it is the first in its class approved primarily for migraine prevention. This article will discuss the evidence, safety, and rationale of atogepant for use in clinical practice.
Recommended Citation
Cohen, Fred and Yuan, Hsiangkuo, "Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations" (2022). Department of Neurology Faculty Papers. Paper 289.
https://jdc.jefferson.edu/neurologyfp/289
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
PubMed ID
35493707
Language
English
Comments
This article is the author’s final published version in Therapeutics and Clinical Risk Management, Volume 18, April 2022, Pages 447 - 456.
The published version is available at https://doi.org/10.2147/TCRM.S348724. Copyright © Cohen and Yuan.